Silvercrest Asset Management’s Haemonetics HAE Stock Holding History

Silvercrest Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37M	Buy	493,796 +2,049	+0.4%	+$132K	0.24%	104
2026 Q1	$27.7M	Sell	491,747 -81,906	-14%	-$5.33M	0.2%	141
2025 Q4	$46M	Sell	573,653 -67,969	-11%	-$4.57M	0.32%	82
2025 Q3	$31.3M	Buy	641,622 +43,212	+7%	+$2.67M	0.21%	140
2025 Q2	$44.6M	Sell	598,410 -33,606	-5%	-$2.23M	0.3%	100
2025 Q1	$40.2M	Sell	632,016 -11,211	-2%	-$762K	0.29%	105
2024 Q4	$50.2M	Buy	643,227 +152,042	+31%	+$12.2M	0.34%	97
2024 Q3	$39.5M	Sell	491,185 -6,904	-1%	-$558K	0.27%	121
2024 Q2	$41.2M	Buy	498,089 +44,595	+10%	+$3.92M	0.28%	119
2024 Q1	$38.7M	Buy	+453,494	New	+$35.6M	0.26%	130

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silvercrest Asset Management's HAE Position: Q2 2026 in Review

Silvercrest Asset Management increased its Haemonetics (HAE) stake by 0.42% in Q2 2026, buying an estimated $132K and bringing the position to 493,796 shares worth $37M. The position accounts for 0.24% of the portfolio, ranked #104.

Silvercrest Asset Management first reported a position in HAE in Q1 2024 and has held it in 10 quarters since. The position peaked at $50.2M in Q4 2024. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Silvercrest Asset Management held 493,796 shares of Haemonetics worth $37M as of Q2 2026.
Silvercrest Asset Management bought 2,049 Haemonetics shares in Q2 2026, an estimated $132K.
Haemonetics made up 0.24% of Silvercrest Asset Management's portfolio in Q2 2026, its #104 holding.
Silvercrest Asset Management first reported a position in Haemonetics in Q1 2024 and has held it in 10 quarters since.
Silvercrest Asset Management's Haemonetics position peaked at $50.2M in Q4 2024.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.